Prevalence of Atrial Fibrillation and use of Oral Antithrombotic Therapy in Patients with Acute Coronary Syndrome

Purpose: To assess the prevalence of atrial fibrillation (AF) and use of antithrombotic agents in adult patients with acute coronary syndrome (ACS).

Materials and Methods. We consecutively enrolled all ACS patients (n=1155) who were hospitalized in two Moscowbased percutaneous coronary intervention centers (each center performs over 500 PCIs a year) between October 2017 and February 2018. AF was diagnosed in 204 patients (17.7%). The risk of thromboembolic complications was assessed using the CHA2DS2-VASc Score. The risk of hemorrhagic complications was assessed using the HAS-BLED Score. The data were processed using StatSoft Statistica 10.0 and IBM SPSS Statistics v.23 software.

Results. The prevalence of diagnosed AF was 13.6%, while the prevalence of undiagnosed AF was 4.1%. Of the 179 discharged patients with AF, only 2 had a low risk of ischemic stroke (IS). One hundred and fifty patients (83.8%) eligible for oral anticoagulant therapy received oral anticoagulants. Patients with diagnosed AF were administered oral anticoagulants (OACs) significantly more often than patients with undiagnosed AF [125 (91.9%) vs. 25 (58.1%), р<0.001]. Novel oral anticoagulants (NOACs) were administered four times more often than vitamin K antagonists [120 (80.0%) vs. 29 (19.3%), р<0.001]. Rivaroxaban was used in 51.3% of cases. Of the 29 patients treated with warfarin, only 3 (10.3%) achieved the target international normalized ratio (INR) at discharge. Of the 107 patients who underwent percutaneous coronary intervention (PCI), 77 patients (80%) received an OAC and two antiplatelet agents (with 74% receiving this three-agent therapy for one month), 11 patients (10.3%) received an OAC and an antiplatelet agent, and 18 patients (16.8%) received two antiplatelet agents. The only antiplatelet agent used as part of the three-agent therapy was clopidogrel. The three-agent therapy without PCI was administered in 43.1% of cases.

Conclusion. We found that the prevalence of AF in patients with ACS was high. The fact that doctors administered NOACs suggests that they are aware of the need to use these agents to prevent thromboembolic complications in AF patients.

1. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the Management of Atrial FIbrillation Developedin Collaboration With Eacts. Russian Journal of Cardiology 2017;(7):7–86. (Kirchhof P., Benussi S., Kotecha D. и др. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал. 2017;(7):7–86.) DOI: 10.15829/1560-4071-2017-7-7-86.

2. Holmes D.R. Jr, Kereiakes D.J., Kleiman N.S. et al. Combining Antiplatelet and Anticoagulant Therapies. Journal of the Ameri can College of Cardiology 2009;54(2):95–109. DOI: 10.1016/j.jacc.2009.03.044.

3. Lamberts M., Olesen J.B., Ruwald M.H. et al. Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention A Nationwide Cohort Study. Circulation 2012;126(10):1185–1193. DOI:10.1161/CIRCULATIONAHA.112.114967.

4. Dewilde W.J., Oirbans T., Verheugt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. The Lancet 2013;381(9872):1107– 1115. DOI:10.1016/s0140-6736(12)62177-1.

5. Gibson C.M., Mehran R., Bode C. et al. Prevention of Bleeding in Patient s with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine 2016;375(25):2423–2434. DOI: 10.1056/NEJMoa1611594.

6. Cannon C.P., Bhatt D.L., Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. The New England Journal of Medicine 2017;377(16):1513–1524. DOI: 10.1056/NEJMoa1708454.

7. Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal 2018;39(3):213–254. DOI:10.1093/eurheartj/ehx419.

8. Schmitt J., Duray G., Gersh B.J., Hohnloser S.H. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. European Heart Journal 2009;30(9):1038–1045. DOI: 10.1093/eurheartj/ehn579.

9. Jerlikh A.D., Gratsiansky N.A. Ostryj koronarnyj sindrom bez podemov segmenta ST v praktike rossijskih stacionarov: sravnitel’nye dannye registrov REKORD-2 i REKORD. Kardiologiya 2012;52(10):9– 16. Russian (Эрлих А.Д., Грацианский Н.А. Ост рый коронарный синдром без подъемов сегмента ST в практике российских стационаров: сравнительные данные регистров РЕКОРД-2 и РЕКОРД. Кардиология 2012;52(10):9–16).

10. Martsevich S. Yu., Ginsburg M. L., Kutishenko N. P. et al. Issledovanie LIS (Ljubereckoe issledovanie smertnosti bol’nyh, perenesshih ostryj infarkt miokarda): portret zaboleпротивhego. Kardiovaskulyarnaya terapiya i profilaktika 2011;10(6):89–93. Russian (Марцевич С.Ю., Гинзбург М.Л., Кутишенко Н.П. и др. Исследование ЛИС (Люберецкое исследование смертности больных, перенесших острый инфаркт миокарда): портрет заболевшего. Кардиоваскулярная терапия и профилактика 2011;10(6):89–93).

11. Jerlikh A.D., Gratsiansky N.A. Rossiiskii registr ostrogo koronarnogo sindroma “REKORD-3”. Harakteristika pacientov i lechenie do vypiski iz stacionara. Kardiologiya 2016;56(4):16–24. Russian (Эрлих А.Д., Грацианский Н.А. Российский регистр острого коронарного синдрома «РЕКОРД-3». Характеристика пациентов и лечение до выписки из стационара. Кардиология 2016;56(4):16–24). DOI: 10.18565/cardio.2016.4.16-24. ISSN: 0022-9040.

12. Hudzik B., Budaj A., Gierlotka M. et al. Antithrombotic management in patients with atrial fibrillation and acute coronary syndromes – the results from the Polish Registry of Acute Coronary Syndromes (PL-ACS). European Heart Journal 2018;39(1):1008. DOI: 10.1093/eurheartj/ehy563.P4801.

13. Jabre P., Jouven X., Adnet F. et al. Atrial Fibrillation and Death After Myocar dial Infarction. A Community Study. Circulation 2011;123(19):2094– 2100. DOI: 10.1161/CIRCULATIONAHA.110.990192.

14. Sindet-Pedersen C., Staerk L., Lamberts M. et al. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. Heart 2018;104(11):912–920. DOI: 10.1136/heartjnl-2017-311976.

15. Dewilde W.J., Oirbans T., Verheugt F.W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an openlabel, randomised, controlled trial. Lancet 2013;381(9872):1107–1115. DOI: 10.1016/S0140-6736(12)62177-1.

16. Kerneis M., Gibson C.M., Chi G. et al. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Inter vention Insights From the PIONEER AF-PCI Trial. JACC: Cardio vascular Interventions 2018;1(7):626–634. DOI: 10.1016/j.jcin.2017.11.009.

17. Lip G.Y.H., Collet J.P., Haude M. et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients resenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 2018. DOI: 10.1093/europace/euy174.

18. Angiolillo D.J., Goodman S.G., Bhatt D.L. et al. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Inter ven tion A North American Perspective-2018 Update. Circu lation 2018;138(5):527–536. DOI: 10.1161/CIRCULATIONAHA.118.034722.

19. Ibanez B., James S., Agewall S. et al. 2017 ESC Guidelines for themanagement of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 2018;39(2):119–177. DOI: 10.1093/eurheartj/ehx393.

20. Guenancia C., Toucas C., Fauchier L. et al. High rate of recurrence at long-term follow-up after new-onset atrial fibrillation during acute myocardial infarction. Europace 2018;0:1–10. DOI:10.1093/europace/euy168.